Biotech News

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Arcutis Biotherapeutics (ARQT)Arcutis Biotherapeutics2026-07-15 20:00 ESTEarnings

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close: 26.43 USD
Market cap: 2.6B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Related news

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics

Recent company news

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Expands Board of Directors with Appointment of Chris Peetz